Advertisement

Topics

Latest "Everolimus and LongActing Octreotide Trial in Polycystic Livers" News Stories

12:37 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "Everolimus and LongActing Octreotide Trial in Polycystic Livers" found in our extensive news archives from over 250 global news sources.

More Information about Everolimus and LongActing Octreotide Trial in Polycystic Livers on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Everolimus and LongActing Octreotide Trial in Polycystic Livers for you to read. Along with our medical data and news we also list Everolimus and LongActing Octreotide Trial in Polycystic Livers Clinical Trials, which are updated daily. BioPortfolio also has a large database of Everolimus and LongActing Octreotide Trial in Polycystic Livers Companies for you to search.

Showing "Everolimus LongActing Octreotide Trial Polycystic Livers" News Articles 1–25 of 8,800+

Saturday 23rd March 2019

Innovent Starts US Trial of "Pivotal" CD47 Immunotherapy

Innovent Biologics of Suzhou has begun a US Phase I trial of its anti-CD47 mAb candidate (IBI188) in patients with advanced malignant tumors. By binding to the CD47 antigen on tumor cells, IBI188 is expected to block the CD47-SIRPα signaling pathway, inhibit the "do not eat me" signal, and promote the phagocytosis of tumor cells by macrophages. Innovent called IBI188 a "pivotal product in ou...


Friday 22nd March 2019

[Articles] Monthly sulfadoxine–pyrimethamine versus dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial

Monthly intermittent preventive treatment with dihydroartemisinin–piperaquine was safe but did not lead to significant improvements in birth outcomes compared with sulfadoxine–pyrimethamine.

[Articles] β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Long-term treatment with β blockers could increase decompensation-free survival in patients with compensated cirrhosis and CSPH, mainly by reducing the incidence of ascites.


[Comment] The STREAM trial: missed opportunities and lessons for future clinical trials

Final results of the STREAM trial were presented at the 2018, 49th Union World Conference on Lung Health, held in The Hague, The Netherlands. STREAM is a randomised controlled trial comparing the 18–24 month WHO-recommended multidrug-resistant tuberculosis (MDR-TB) treatment regimen with a 9–12 month regimen similar to that first described in Bangladesh.1 Under programmatic conditions, the lon...

Improved PCOS symptoms correlate with gut bacterial composition

(The Endocrine Society) Symptoms of polycystic ovary syndrome (PCOS) improved with exposure to healthy bacteria in the gut, according to a study in a mouse model of this common women's endocrine disorder. The study results will be presented Monday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.

Gossamer Bio Announces 2018 Annual Financial Results

Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on recent corporate developments. ...

An Alzheimer’s Drug Trial Gave Me Hope, and Then It Ended

I was a small piece in the search to find a cure. Now I feel as if I’m getting erased, and medical science doesn’t have any answers.

Eisai Initiates Phase 3 Trial of BAN2401 in Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States, “Biogen”). Clar...

FDA Warns About the Risks Associated with the Investigational Use of Venclexta in Multiple Myeloma

[3/21/2019] The U.S. Food and Drug Administration is alerting health care professionals, oncology clinical investigators and patients about the risks associated with the investigational use of Venclexta (venetoclax) for the treatment of patients with multiple myeloma based on data from a clinical trial. Venclexta is not approved for the treatment of multiple myeloma. FDA reviewed data …

Conatus’ Investigational Emricasan Fails to Meet Primary Endpoint in Phase 2b Trial in NASH Fibrosis

SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis. The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with plac...

Biogen Halts Studies of Closely Watched Alzheimer's Drug, a Blow to Hopes for New Treatment

Trial failure raises doubts about amyloid as a target for drug development -- Read more on ScientificAmerican.com

#news #biotech Conatus and Novartis suffer another midphase NASH flop

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Conatus and Novartis suffer another midphase NASH flop .Conatus Pharmaceuticals’ emricasan has failed another midphase clinical trial. The latest setback saw the Novartis-partnered liver disease drug fail to … Continue reading →

Alios Buy Best Forgotten For Johnson & Johnson As RSV Failure Costs It Dear

Johnson & Johnson has suspended Phase IIb trial of its RSV asset written off a further $700m against its RSV...   

Novartis, Conatus' emricasan fails mid-stage NASH fibrosis trial https://firstwordpharma.com/node/1630929?tsid=28®ion_id=6 …

Novartis, Conatus' emricasan fails mid-stage NASH fibrosis trial https://firstwordpharma.com/node/1630929?tsid=28&region_id=6 …

Pancreatic cancer trial in UK achieves patient milestone

The trial is run by Precision-Panc, a research program and clinical trials project led by the University of Glasgow with major funding from Cancer Research UK. It brings The post Pancreatic cancer trial in UK achieves patient milestone appeared first on Compelo Medical Devices - Latest industry news and analysis.

Biogen and Eisai terminate trial of Alzheimer’s drug on efficacy grounds

Biogen and Eisai have announced they are discontinuing two Phase III trials, Engage and Emerge, evaluating the safety and efficacy...Read More... The post Biogen and Eisai terminate trial of Alzheimer’s drug on efficacy grounds appeared first on Pharmaceutical Technology.

$NVCR Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer https://www.businesswire.com/news/home/20190322005019/en/Novocure-Initiates-Phase-3-Pivotal-Trial-Recurrent …

$NVCR Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer https://www.businesswire.com/news/home/20190322005019/en/Novocure-Initiates-Phase-3-Pivotal-Trial-Recurrent …

Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer Ovarian cancer is the fifth leading cause of cancer death among women Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor ...

Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Application supported by the Phase 3 MAIA study for daratumumab in combination with lenalidomide and dexamethasone for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation ...

DATA: ACC Results Recap Part III: RADIANCE-HTM SOLO Results Support ReCor’s Renal Denervation System

Medtech Insight's Results Recap is a regular feature covering the major device trial results compiled by MedDeviceTracker. This is the...   

$CNAT downgraded to Hold at SunTrust after failed ENCORE-NF trial

$CNAT downgraded to Hold at SunTrust after failed ENCORE-NF trial

-#FDA puts multiple myeloma trial on hold after patient deaths -Biogen and Eisai discontinue Phase 3 Alzheimer's trial -Sandoz CEO Richard Francis to step down -Pfizer #CEO Ian Read's pay packet cut from $27.9m to $19.5m http://bit.ly/2U30g5f pic.twitt

- #FDA puts multiple myeloma trial on hold after patient deaths -Biogen and Eisai discontinue Phase 3 Alzheimer's trial -Sandoz CEO Richard Francis to step down -Pfizer #CEO Ian Read's pay packet cut from $27.9m to $19.5m http://bit.ly/2U30g5f  pic.twitter.com/RQo2q97Q8B

FDA assures flexibility in trial design review for stem cell studies

Final guidance issued by the FDA on stem cell therapy trial design included an assurance from the agency that it will be more -More- 

Updated data out on early-stage trial for GSK's myeloma candidate

Updated results from GlaxoSmithKline's Phase I clinical trial evaluating its candidate GSK2857916 for multiple myeloma showed -More- 

Targeted lymphoma drug gets green light for NHS in England

News report People with a certain type of lymphoma will now have access to a targeted cancer drug on the NHS in England. Brentuximab vedotin (Adcetris) was approved by the Nation


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks